Table 3.
Lytic activity of seven commercial bacteriophage cocktails against 34 Staphylococcus aureus strains acquired from peritoneal dialysis patient samples.
| S. aureus Strain Code | Bacteriophages | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Biofilm Production Degree | Eliava BioPreparations Ltd. | Microgen Ltd. | |||||||
| Staphylococcal | Pyo | Ses | Fersisi | Enko | Intesti | Pyobacteriophag | |||
| 1.2 × 107 | 3.4 × 107 | 4.0 × 107 | 2.4 × 107 | 1.4 × 107 | 2.0 × 107 | 2.0 × 107 | |||
| Not Adapted | Adapted | ||||||||
| 1N | Strong | PL | PL | PL | PL | PL | PL | PL | |
| 3N | Strong | PL | PL | PL | PL | PL | PL | PL | |
| 6N | Moderate | R a | PL | PL | PL | PL | PL | PL | PL |
| 6G | Strong | R a | PL | PL | PL | PL | PL | PL | PL |
| 8N | Strong | PL | PL | PL | PL | PL | PL | PL | |
| 8G | Strong | PL | PL | PL | PL | PL | PL | PL | |
| 12N | Moderate | IP a | PL | PL | PL | PL | PL | PL | IP |
| 12PD | Strong | R a | PL | PL | PL | PL | PL | PL | PL |
| 14N | Moderate | PL | PL | PL | PL | PL | PL | PL | |
| 15N | Strong | R a | PL | PL | PL | PL | PL | PL | PL |
| 15G | Strong | R a | PL | PL | PL | PL | PL | PL | PL |
| 17N | Strong | R a | PL | IP | PL | PL | PL | PL | IP |
| 19N | Moderate | R a | PL | PL | PL | PL | PL | PL | IP |
| 25N | Strong | PL | PL | PL | PL | PL | PL | PL | |
| 25PD | Strong | PL | PL | PL | PL | PL | PL | PL | |
| 25G | Strong | PL | PL | PL | PL | PL | PL | PL | |
| 26PD | Strong | PL | PL | PL | PL | PL | PL | PL | |
| 27N | Strong | PL | PL | IP | PL | IP | PL | PL | |
| 27G | Strong | PL | CL | PL | PL | CL | PL | PL | |
| 35N | Strong | IP a | PL | PL | PL | PL | PL | PL | PL |
| 35G | Strong | PL | PL | PL | PL | PL | PL | PL | |
| 36N | Moderate | PL | PL | PL | PL | PL | PL | PL | |
| 47G | Strong | CL | PL | PL | PL | PL | PL | PL | |
| 48G | Strong | CL | PL | PL | PL | PL | PL | PL | |
| 58N | Strong | PL | PL | PL | PL | PL | PL | PL | |
| 59G | Weak | CL | PL | IP | PL | PL | PL | PL | |
| 59N | Weak | CL | CL | PL | IP | PL | PL | PL | |
| 67G | Weak | R a | PL | PL | PL | PL | PL | PL | PL |
| 67N | Moderate | R a | PL | PL | PL | PL | PL | PL | PL |
| 67PD | Moderate | PL | PL | PL | PL | PL | PL | PL | |
| 70N | Strong | PL | PL | PL | PL | PL | PL | PL | |
| 71PD | Moderate | PL | PL | PL | PL | PL | PL | PL | |
| 71G | Moderate | PL | PL | PL | PL | PL | PL | PL | |
| 71N | Moderate | PL | PL | PL | PL | PL | PL | PL | |
| Phage lytic activity | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | |
| CL (+++) | 4 (12) | 0 (0) | 2 (6) | 0 (0) | 0 (0) | 1 (3) | 0 (0) | 0 (0) | |
| PL (++) | 19 (56) | 11 (100) | 31 (91) | 32 (94) | 33 (97) | 32 (94) | 34 (100) | 31 (91) | |
| IP (+) | 2 a (6) | 0 (0) | 1 (3) | 2 (6) | 1 (3) | 1 (3) | 0 (0) | 3 (9) | |
| R (−) | 9 a (26) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | |
a Staphylococcal Bacteriophage (Eliava) taken to adaptation procedure after showing spot test result as individual plaques (+) or no lysis (−) against 11 Staphylococcus aureus strains acquired from peritoneal dialysis patients samples: CL (+++), confluent lysis; PL (++), partial lysis; IP (+), individual plaques; R (−), resistant or no lysis.